To further test the effect of increased dietary glutamine, we used two melanoma patient-derived xenograft (PDX) models with different genetic backgrounds, PDX_TM00702 (with wild-type BRAF) and PDX_TM01612 (with BRAF V600E mutation), and placed mice on either control or glutamine-rich diet when tumours reached an average of 50 mm3. Here, BRAF is linked to melanoma.